Switch theme
Sign up to access all valuation multiples
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
2012
6
Last FY Revenue n/a
LTM EBITDA -$27.7M
$65.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SynAct Pharma has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$27.7M.
In the most recent fiscal year, SynAct Pharma achieved revenue of n/a and an EBITDA of -$9.2M.
SynAct Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SynAct Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$27.7M | XXX | -$9.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$27.7M | XXX | -$9.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$8.7M | XXX | -$8.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SynAct Pharma's stock price is SEK 14 (or $1).
SynAct Pharma has current market cap of SEK 685M (or $70.7M), and EV of SEK 636M (or $65.6M).
See SynAct Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65.6M | $70.7M | XXX | XXX | XXX | XXX | $-0.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SynAct Pharma has market cap of $70.7M and EV of $65.6M.
SynAct Pharma's trades at n/a EV/Revenue multiple, and -7.1x EV/EBITDA.
Equity research analysts estimate SynAct Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SynAct Pharma has a P/E ratio of -8.1x.
See valuation multiples for SynAct Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $70.7M | XXX | $70.7M | XXX | XXX | XXX |
| EV (current) | $65.6M | XXX | $65.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | -7.1x | XXX | XXX | XXX |
| EV/EBIT | -2.4x | XXX | -7.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.1x | XXX | -8.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSynAct Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
SynAct Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SynAct Pharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SynAct Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -48% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SynAct Pharma acquired XXX companies to date.
Last acquisition by SynAct Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . SynAct Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SynAct Pharma founded? | SynAct Pharma was founded in 2012. |
| Where is SynAct Pharma headquartered? | SynAct Pharma is headquartered in Sweden. |
| How many employees does SynAct Pharma have? | As of today, SynAct Pharma has 6 employees. |
| Who is the CEO of SynAct Pharma? | SynAct Pharma's CEO is Dr. Torbjorn Bjerke. |
| Is SynAct Pharma publicy listed? | Yes, SynAct Pharma is a public company listed on STO. |
| What is the stock symbol of SynAct Pharma? | SynAct Pharma trades under SYNACT ticker. |
| When did SynAct Pharma go public? | SynAct Pharma went public in 2016. |
| Who are competitors of SynAct Pharma? | Similar companies to SynAct Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SynAct Pharma? | SynAct Pharma's current market cap is $70.7M |
| Is SynAct Pharma profitable? | Yes, SynAct Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SynAct Pharma? | SynAct Pharma's last 12 months EBITDA is -$27.7M. |
| What is the current EV/EBITDA multiple of SynAct Pharma? | Current EBITDA multiple of SynAct Pharma is -2.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
